Bright Health Group Reports Third Quarter 2023 Results
Q3’23 Revenue from Continuing Business of $269.4 million, up 39% year over year Value-Based Consumers served of 355,000, an increase of 208.7% on a comparable... Read more.
Global Collaborative Robot Market Analysis: Trends, Drivers, and Opportunities by Region – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Collaborative Robot (Cobot) Market – A Global and Regional Analysis: Focus on Industry, Application, Type, Payload,... Read more.
Tiny to Present at TD Securities Technology Conference
VICTORIA, British Columbia–(BUSINESS WIRE)–Tiny Ltd. (“Tiny” or the “Company”) (TSXV: TINY), a Canadian technology holding company, today announced... Read more.
ImpactAssets Surpasses $3B AUM, Building on Momentum Showcased in New 2023 Impact Report
Annual report captures the transformative progress produced by the firm’s current investment portfolio of 886 companies and funds, with a key focus on climate... Read more.
Premier, Inc. Reports Fiscal-Year 2024 First-Quarter Results
CHARLOTTE, N.C.–(BUSINESS WIRE)–Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results... Read more.
InfuSystem Reports Third Quarter 2023 Financial Results
Record Net Revenues of $31.9 million Representing 17% Growth from the Prior Year Operating Income Increased 80% – Net Income Increased 56% – Adjusted... Read more.
Hostess Brands Reports Third Quarter 2023 Results
Company Recently Announced a Definitive Agreement to be Acquired by The J. M. Smucker Company LENEXA, Kan.–(BUSINESS WIRE)–Hostess Brands, Inc. (NASDAQ:... Read more.
Ault Alliance Enters Into an Agreement for a Financing of up to $50 Million
LAS VEGAS–(BUSINESS WIRE)–$AGREE #50_million_dollars_new_financing—Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“AAI”... Read more.
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
ZURZUVAE™ (zuranolone), first and only oral treatment approved for adults with postpartum depression (PPD), designated Schedule IV by the DEA; progressing towards... Read more.
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused... Read more.